1. 2004
2. Cyhoeddwyd

   Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease

   Hughes, D. & Hughes, D. A., 1 Tach 2004, Yn: Value in Health. 7, 6, t. 753

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   From efficacy to effectiveness and cost-effectiveness: modelling possibilities

   Hughes, D. & Hughes, D. A., 1 Tach 2004.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   HLA-B*5701 and abacavir hypersensitivity - Reply.

   Hughes, D., Hughes, D. A., Park, B. K. & Pirmohamed, M., 1 Tach 2004, Yn: Pharmacogenetics. 14, 11, t. 784

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. 2005
6. Cyhoeddwyd

   Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease.

   Hughes, D., Hughes, D. A., Bodger, K., Bytzer, P., De Herdt, D. & Dubois, D., 1 Ion 2005, Yn: Pharmacoeconomics. 23, 10, t. 1031-1041

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

   Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2005, 2005 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

8. Cyhoeddwyd

   Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Sweden.

   Hughes, D. & Hughes, D. A., 1 Ion 2005, 2005 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

9. Cyhoeddwyd

   Welsh Health Economics Network (WHEN): Scoping Report.

   Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

10. Cyhoeddwyd

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease.

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Chwef 2005, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 5, 1, t. 29-38

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Empirical analysis of the relationship between dose and duration of drug action

    Hughes, D. & Hughes, D. A., 1 Meh 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

12. Cyhoeddwyd

    Pharmacokinetics, patient compliance and pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Meh 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

13. Cyhoeddwyd

    Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.

    Hughes, D. & Hughes, D. A., 1 Gorff 2005, Yn: European Journal of Cancer. 41, 11, t. 1655

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

14. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Gorff 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

15. Cyhoeddwyd

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

16. Cyhoeddwyd

    Incorporating measures of compliance and persistence in pharmacoeconomic evaluations

    Hughes, D., Hughes, D. A. & Cowell, W., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

17. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

18. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

19. Cyhoeddwyd

    Trends and influences on use of antidiabetic drugs in England, 1992-2003.

    Walley, T., Hughes, D. & Kendall, H., 1 Tach 2005, Yn: Pharmacoepidemiology and Drug Safety. 14, 11, t. 769-773

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

20. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 11 Tach 2005, Yn: Value in Health. 8, 6, t. A192

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

21. 2006
22. Cyhoeddwyd

    Beyond registration: measuring the public health potential of new treatments for Malaria in Africa.

    Hughes, D., Lang, T., Hughes, D. A., Kanyok, T., Kengeya-Kayondo, J., Marsh, V., Haaland, A., Pirmohamed, M. & Winstanley, P., 1 Ion 2006, Yn: Lancet Infectious Diseases. 6, 1, t. 46-52

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

23. Cyhoeddwyd

    Health economic aspects of patient non-compliance

    Hughes, D., Hughes, D. A., Davies, M. (gol.) & Kermani, F. (gol.), 1 Ion 2006, Patient Compliance: Sweetening the Pill. 2006 gol. Gower Publishing, t. 23-40

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

24. Cyhoeddwyd

    Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

25. Cyhoeddwyd

    Improving Outcomes for People with Sarcoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

26. Cyhoeddwyd

    Less is more: Medicines that require less frequent administration improve adherence, but are they better?

    Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 3, t. 211-213

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

27. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Ion 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

28. Cyhoeddwyd

    Rationing of drugs for rare diseases.

    Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 4, t. 315-316

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

29. Cyhoeddwyd

    Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Chwef 2006, Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

30. Cyhoeddwyd

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Maw 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

31. Cyhoeddwyd

    Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.

    Simpson, J. A., Hughes, D., Manyando, C., Bojang, K., Aarons, L., Winstanley, P., Edwards, G., Watkins, W. A. & Ward, S., 1 Maw 2006, Yn: British Journal of Clinical Pharmacology. 61, 3, t. 289-300

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

32. Cyhoeddwyd

    Health and economic outcomes: Why compliance matters

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

33. Cyhoeddwyd

    Physchiatrist prescribing preferences and attitudes toward promotion

    Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

34. Cyhoeddwyd

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

35. Cyhoeddwyd

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

36. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

37. Cyhoeddwyd

    Orphan drugs revisited: author's response.

    Hughes, D. & Hughes, D. A., 1 Mai 2006, Yn: Quarterly Journal of Medicine. 99, 5, t. 350-351

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

38. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

39. Cyhoeddwyd

    Prescription fee exemption research study

    Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

40. Cyhoeddwyd

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Medi 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

41. Cyhoeddwyd

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Tach 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

42. 2007
43. Cyhoeddwyd

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

44. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

45. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

46. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

47. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

48. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

49. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

50. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

51. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

52. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

53. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

54. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn